Immunomodulators on HIV-1 Reservoir

Inclusion Criteria: * Men and women age ≥ 18 and ≤ 65 years. * HIV-1 infection, confirmed by any licensed rapid HIV test and then a licensed Western blot. * Virologic suppression defined as HIV-1 RNA level below the limit of quantification prior to study entry. * CD4+ T cell count \> 200 cells/mm3 prior to study entry. * Ability and willingness of participant or legal representative to provide written informed consent and attend study visits as scheduled at a participating site. Willingness of participant to accept the side effects of drugs. * All participants of reproductive potential, who are participating in sexual activity that could lead to pregnancy, must agree to use at least one reliable method of contraception from 4 weeks before the start of the study to 4 weeks after the end of the study. Exclusion Criteria: * Breastfeeding or pregnancy, or planned pregnancy during the study. * Poor treatment adherence. * Use of immunomodulators or systemic cytotoxic chemotherapy ≤ 6 months prior to study entry. * Any current diagnosis or past history of a significant cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, neuropsychiatric, psychiatric, or other serious illness. The following laboratory values obtained prior to entry: * Absolute neutrophil count (ANC) ≤ 1000/mm3 * Platelets ≤ 75,000/mm3 * Known allergy/sensitivity or any hypersensitivity to components of study drug or their formulation. * Unwilling to provide written informed consent.